Episode Details

Bivalent new vaccine, Moderna press release https://investors.modernatx.com/news/news-details/2022/Moderna-Announces-Omicron-Containing-Bivalent-Booster-Candidate-mRNA-1273.214-Demonstrates-Superior-Antibody-Response-Against-Omicron/default.aspx Omicron-containing bivalent COVID booster candidate, mRNA-1273.214 (original mRNA-1273 vaccine), Superior neutralizing antibody response in baseline seronegative participants. increased neutralizing geometric mean titers (GMT) against Omicron approximately 8-fold above baseline levels. mRNA-1273.214 50 μg booster dose, well-tolerated in the 437 study participants The safety and reactogenicity profile of the mRNA-1273.214 50 μg booster dose was similar to that of mRNA-1273 50 μg BA.1 SARS-CoV-2 variants of concern and variants under investigation in England Technical briefing 44 https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1093275/covid-technical-briefing-44-22-july-2022.pdf BA.2 3.4% BA.4 17.2% BA.5 78.7% Other 0.7% US variants https://covid.cdc.gov/covid-data-tracker/#variant-proportions BA.5 88.8% BA.4 5.3% BA.4.6 5.1% BA.2.12.1 0.8% BA.2 0% BA.1s 0% Delta 0% Epidemiology of Myocarditis and Pericarditis Following mRNA Vaccination by Vaccine Product, Schedule, and Interdose Interval Among Adolescents and Adults in Ontario, Canada https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2793551 Population-based cohort study of 297 individuals in Ontario, Canada, with myocarditis or pericarditis following COVID-19 vaccination, found higher rates of myocarditis or pericarditis associated with receipt of mRNA-1273 compared with BNT162b2 as a second dose, particularly among male individuals aged 18 to 24 years. The results suggest that there may be product-specific differences in rates of myocarditis or pericarditis after receiving mRNA vaccines First bivalent COVID-19 booster vaccine approved by UK medicines regulator https://www.gov.uk/government/news/first-bivalent-covid-19-booster-vaccine-approved-by-uk-medicines-regulator Moderna bivalent approved for adult booster doses by MHRA Spikevax bivalent Original/Omicron 25 micrograms targets the original virus strain 25 micrograms targets Omicron Omicron (BA.1) and the original 2020 strain (was also found to generate a good immune response against BA.4 and BA.5) Safety monitoring side effects observed were the same as those seen for the original Moderna booster dose, and were typically mild and self-resolving, and no serious safety concerns were identified. Global covid deaths https://www.worldometers.info/coronavirus/ 6,466,947 Evidence cited by HMRA https://www.thelancet.com/journals/laninf/article/PIIS1473-3099%2822%2900320-6/fulltext Based on official reported COVID-19 deaths, we estimated that vaccinations prevented 14·4 million deaths from COVID-19 in 185 countries, between Dec 8, 2020, and Dec 8, 2021. 19·8 million when we used excess deaths as an estimate Joint Committee on Vaccination and Immunisation (JCVI) updated statement on the COVID-19 vaccination programme for autumn 2022 For autumn 2022 https://www.gov.uk/government/publications/jcvi-updated-statement-on-the-covid-19-vaccination-programme-for-autumn-2022/joint-committee-on-vaccination-and-immunisation-jcvi-updated-statement-on-the-covid-19-vaccination-programme-for-autumn-2022 JCVI advises the following groups should be offered a COVID-19 booster vaccine: residents in a care home for older adults and staff working in care homes for older adults frontline health and social care workers all adults aged 50 years and over persons aged 5 to 49 years in a clinical risk group persons aged 5 to 49 years who are household contacts of people with immunosuppression persons aged 16 to 49 years who are carers Time to collect PROSPECTIVE data Cardiova

Learn more about your ad choices. Visit megaphone.fm/adchoices